|
|
Article: Antares Pharma Announces its Licensee, BioSante Pharmaceuticals, Recently Presented Positive Results from Phase II Trial of LibiGel(TM), a Topical Testosterone Gel that Utilizes Antares Pharma's Gel Technology System.
- Article from:
- PR Newswire
- Article date:
- October 23, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Antares Pharma Inc. (BULLETIN BOARD: ANTR) announced today that its U.S. licensee for its topical testosterone gel product, BioSante Pharmaceuticals, Inc. , recently presented positive results from an ongoing Phase II clinical trial of LibiGel(TM) (topical testosterone gel) for the treatment of female sexual dysfunction. LibiGel utilizes Antares Pharma's proprietary advanced transdermal delivery (ATD(TM)) gel technology designed to allow delivery of hormones and other products across the skin.
BioSante's data was presented at a meeting of the International Society for the Study of Women's Sexual Health (ISSWSH) in Amsterdam on October 17, 2003. The interim ...
Related newspaper, magazine, and journal articles:
|
|
Article: BioSante Pharmaceuticals Releases Update of LibiGel ...
Health & Beauty Close-Up;
June 18, 2009 ;
700+ words
...Antares Pharma, Inc. partner BioSante Pharmaceuticals announced that based upon ... LibiGel, which uses the Antares Pharma ATD system, an FDA approved ... an additional four years. Antares Pharma is a product development ...
|
|